| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$48 |
Application for quotation of securities - IMU
|
27 Aug 2025 11:45AM |
$0.263 |
$0.135 |
fallen by
48.57%
|
|
| Amaero Ltd (3DA) ORDINARY FULLY PAID |
Industrials |
$348 |
Application for quotation of securities - 3DA
|
27 Aug 2025 11:40AM |
$0.370 |
$0.365 |
fallen by
1.35%
|
|
| MRG Metals Limited (MRQ) ORDINARY FULLY PAID |
Materials |
$12 |
MRQOD Top 20 and Distribution
|
27 Aug 2025 11:38AM |
$0.003 |
$0.004 |
risen by
33.33%
|
|
| Nine Entertainment Co. Holdings Limited (NEC) ORDINARY FULLY PAID |
Communication Services |
$1,499 |
Notification of cessation of securities - NEC
|
27 Aug 2025 11:37AM |
$1.828 |
$0.945 |
fallen by
48.29%
|
|
| Kogan.com Ltd (KGN) ORDINARY FULLY PAID |
Consumer Discretionary |
$370 |
Change of Director's Interest Notice - RB
|
27 Aug 2025 11:36AM |
$3.980 |
$3.860 |
fallen by
3.02%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$11 |
Update - Proposed issue of securities - CMB
|
27 Aug 2025 11:35AM |
$0.360 |
$0.385 |
risen by
6.94%
|
|
| Magnetic Resources NL (MAU) ORDINARY FULLY PAID |
Materials |
$584 |
Notice Under Section 708A(5)(e)
|
27 Aug 2025 11:33AM |
$1.290 |
$1.975 |
risen by
53.10%
|
|
| Magnetic Resources NL (MAU) ORDINARY FULLY PAID |
Materials |
$584 |
Application for quotation of securities - MAU
|
27 Aug 2025 11:29AM |
$1.290 |
$1.975 |
risen by
53.10%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$11 |
Placement Participant Update
|
27 Aug 2025 11:27AM |
$0.360 |
$0.385 |
risen by
6.94%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Cambium Bio Limited announces an update to its placement participants.
- Certain institutional and sophisticated investors have been added and removed as placement participants.
- There is no change to the total amount of funds raised or the terms of the placement.
- The update is for transparency and compliance with ASX Listing Rules.
- The announcement does not affect the overall outcome or objectives of the placement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| INOVIQ Ltd (IIQ) ORDINARY FULLY PAID |
Health Care |
$48 |
Investor Webinar Presentation
|
27 Aug 2025 11:23AM |
$0.400 |
$0.340 |
fallen by
15%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$1,541 |
Investor Presentation, 27 August 2025
|
27 Aug 2025 11:21AM |
$17.930 |
$12.180 |
fallen by
32.07%
|
|
| Optiscan Imaging Limited (OIL) ORDINARY FULLY PAID |
Health Care |
$115 |
Proposed issue of securities - OIL
|
27 Aug 2025 11:19AM |
$0.080 |
$0.110 |
risen by
37.50%
|
|
| Optiscan Imaging Limited (OIL) ORDINARY FULLY PAID |
Health Care |
$115 |
Optiscan Launches Entitlement Offer to Raise $17.75m
|
27 Aug 2025 11:18AM |
$0.080 |
$0.110 |
risen by
37.50%
|
|
OIL - Price-sensitive ASX Announcement
Full Release
Key Points
- Optiscan Imaging Limited is raising approximately $17.75 million via a fully underwritten entitlement offer.
- The offer is a 1-for-3.3 pro-rata accelerated non-renounceable entitlement offer at $0.065 per new share.
- The issue price represents a discount to the last closing price.
- Funds will be used for ongoing operations, global market expansion, regulatory approvals, product development, and commercialization.
- The offer is fully underwritten and supported by cornerstone institutional investors.
- Key dates, eligibility, and participation instructions are provided for shareholders.
- The company’s strategy focuses on advancing its technology in global healthcare markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Savannah Goldfields Limited (SVG) ORDINARY FULLY PAID |
Materials |
$28 |
Proposed issue of securities - SVG
|
27 Aug 2025 11:16AM |
$0.015 |
$0.013 |
fallen by
13.33%
|
|
| Savannah Goldfields Limited (SVG) ORDINARY FULLY PAID |
Materials |
$28 |
Placement to raise $15 million
|
27 Aug 2025 11:16AM |
$0.015 |
$0.013 |
fallen by
13.33%
|
|
SVG - Price-sensitive ASX Announcement
Full Release
Key Points
- Savannah Goldfields Limited (SVG) is raising $15 million through a placement.
- 125 million new shares will be issued at $0.12 per share to institutional and sophisticated investors.
- The placement price represents a discount to recent share prices.
- Funds will be used to advance gold projects, expand mining, exploration, and for working capital.
- The placement consists of two tranches, with the second tranche subject to shareholder approval.
- Board and management intend to participate in the placement, subject to approval.
- The capital raise is expected to support company operations and value creation.
- Announcement date is 29 April 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| L1 Capital International Fund (Hedged) Active ETF (L1HI) |
Financials |
$30 |
Quarterly Portfolio Disclosure - June 2025
|
27 Aug 2025 11:13AM |
$5.800 |
$5.720 |
fallen by
1.38%
|
|
| Aureka Limited (AKA) ORDINARY FULLY PAID |
Materials |
$16 |
Unmarketable Parcel Completion
|
27 Aug 2025 11:12AM |
$0.089 |
$0.100 |
risen by
12.36%
|
|
| L1 Capital International Fund (Managed Fund) (L1IF) |
Financials |
$461 |
Quarterly Portfolio Disclosure - June 2025
|
27 Aug 2025 11:11AM |
$6.850 |
$6.170 |
fallen by
9.93%
|
|
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$182 |
Second Supplementary Bidder's Statement & Deed Poll
|
27 Aug 2025 11:11AM |
$0.290 |
$0.175 |
fallen by
39.66%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- BETR Entertainment Limited (BETR) submitted a Second Supplementary Bidder's Statement relating to its off-market takeover offer for all ordinary shares in Beyond International Limited (BYI) that it does not already own.
- The supplementary statement provides additional information and updates to the initial Bidder's Statement and the First Supplementary Bidder's Statement.
- The document sets out further details on the consideration and terms of the offer, including the offer period, conditions, and the process for accepting the offer.
- BETR has entered into a Deed Poll in favor of BYI shareholders, confirming its obligations under the offer, particularly regarding payment of the consideration for shares accepted.
- The supplementary statement clarifies the rights of BYI shareholders and provides additional disclosures required under the Corporations Act.
- Shareholders are encouraged to read all statements in full and seek their own independent financial or legal advice regarding the offer.
- The supplementary statement also addresses certain regulatory and procedural matters relevant to the offer, including updates on approvals and consents obtained or outstanding.
- This document is intended to be read together with the previous Bidder's Statements to provide complete information regarding the takeover process.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pointsbet Holdings Limited (PBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$349 |
BBT: Second Supplementary Bidder's Statement & Deed Poll
|
27 Aug 2025 11:11AM |
$1.250 |
$1.005 |
fallen by
19.60%
|
|
PBH - Price-sensitive ASX Announcement
Full Release
Key Points
- BBT Bidco Holdings Pty Ltd (BBT) has made an off-market takeover offer for all PBH shares.
- This is the Second Supplementary Bidder's Statement and includes a Deed Poll.
- The offer price for PBH shares has been increased from previous statements.
- Updated information on tax consequences for PBH shareholders is provided.
- Details regarding the status of competition and regulatory approvals are included.
- The document outlines the terms and conditions of the takeover offer.
- Instructions on how PBH shareholders can accept the offer are provided.
- The supplementary statement updates and supplements the Original and First Supplementary Bidder's Statements.
- The Deed Poll confirms BBT's commitment to honour obligations if the offer becomes unconditional.
- Shareholders are informed of the implications of accepting the offer.
- The document addresses status of conditions precedent as at the date of the statement.
- The statement is intended to ensure PBH shareholders have the latest material information regarding the offer.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sigma Healthcare Limited (SIG) ORDINARY FULLY PAID |
Health Care |
$32,438 |
Dividend/Distribution - SIG
|
27 Aug 2025 11:09AM |
$3.045 |
$2.810 |
fallen by
7.72%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$294 |
Appendix 4G and 2025 Corporate Governance Statement
|
27 Aug 2025 11:05AM |
$1.075 |
$0.930 |
fallen by
13.49%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$62,606 |
Change of Director's Interest Notice
|
27 Aug 2025 10:59AM |
$215.090 |
$129.000 |
fallen by
40.03%
|
|
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$6 |
Appendix 4G and Corporate Governance Statement
|
27 Aug 2025 10:57AM |
$0.120 |
$0.060 |
fallen by
50%
|
|
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$6 |
Appendix 4E and Annual Report
|
27 Aug 2025 10:56AM |
$0.120 |
$0.060 |
fallen by
50%
|
|
IVX - Price-sensitive ASX Announcement
Full Release
Key Points
- Invion Limited is an ASX-listed biotechnology company developing Photosoftâ„¢ technology for photodynamic therapy.
- For the year ended 30 June 2023, Invion reported a net loss of $3,521,536.
- Total revenue for the period was $4,477,805, mainly from research and development services.
- Key operational focus was on advancing pre-clinical and clinical programs for Photosoftâ„¢ across various indications.
- The company’s principal funding and partnership is with The Cho Group, supporting research and development.
- Significant investment was made in R&D, with ongoing projects in cancer, infectious diseases, and inflammatory conditions.
- No dividend was paid or proposed for the financial year.
- The company maintained adequate cash reserves and has no significant borrowings.
- Invion's board and senior management were unchanged during the reporting period.
- Risks include clinical trial outcomes, regulatory approvals, intellectual property protection, and financial sustainability.
- Corporate governance policies and remuneration information are disclosed in the report.
- Audited financial statements and notes are included for full transparency.
- The report affirms Invion’s commitment to expanding its intellectual property portfolio and progressing toward commercialization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.